As per the agreement, Ascenta will conduct its first Phase I trial of AT-406 in adults with AML in combination with the standard AML induction regimen, and expects to start patient enrollment in this study in the first quarter of 2011 in the US.
LLS will also support the investigation of biomarkers for AT-406 for this disease.
LLS executive vice president and chief mission officer Louis DeGennaro said their work with Ascenta will not only determine if their oral multi-IAP inhibitor shows promise in patients with AML but also help identify which of these patients might receive the most benefit.